Cs1-specific chimeric antigen receptor engineered immune effector cells
AssigneeOhio State Innovation Foundation
InventorsJianhua Yu, Craig Hofmeister, Jianhong Chu
Life of this patent
Estimating the term…
Abstract
Disclosed herein are chimeric antigen receptors (CAR) that can specifically recognize tumor-associated antigens (TAA) on multiple myelorna (MM) cells. Also disclosed are Mullane effector cells, such as T cells or Natural Killer (NK) cells, that are engineered to express these CARs. Therefore, also disclosed are methods of providing an anti-tumor immunity in a subject with MM that involves adoptive transfer of the disclosed immune effector cells engineered to express the disclosed CARs.
Claims19
-4. (canceled)
A nucleic acid sequence encoding a chimeric antigen receptor (CAR) polypeptide, wherein the CAR polypeptide is defined by the formula:
- SP-CS1-HG-TM-CSR-ISD;
- or
- SP-CS1-HG-TM-ISD-CSR
- wherein “SP” represents a signal peptide,
- wherein “CS1” represents a CS1 antigen binding domain,
- wherein “HG” represents an optional hinge domain,
- wherein “TM” represents a transmembrane domain,
- wherein “CSR” represents a co-stimulatory signaling region,
- wherein “ISD” represents an intracellular signaling domain, and
- wherein “-” represents a bivalent linker.
-20. (canceled)
Dependencies are inferred from the claim text.